Anti-SARS-CoV-1, Spike RBD (Clone COV1-62) -Purified No Carrier Protein

Specificity: COV1-62 targets the RBD of the SARS-CoV-1 prefusion spike protein (S2), located on the viral surface. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-62 monoclonal antibody targets the receptor-binding domain (RBD) of the SARS-CoV-1 spike protein and does not cross-react with the SARS-CoV-2 spike protein. Although it does not block the ACE2 receptor, COV1-62 acts as a neutralizing antibody, indicating it can inhibit viral entry into host cells through a different mechanism. This could involve preventing the spike protein from achieving the necessary conformations for fusion with the host cell membrane. The neutralizing capability of COV1-62, despite its lack of ACE2 blocking, underscores the importance of targeting various critical sites within the RBD for effective virus neutralization and highlights its potential in therapeutic settings.